Neural Regeneration Research ›› 2022, Vol. 17 ›› Issue (2): 318-319.doi: 10.4103/1673-5374.317972

Previous Articles     Next Articles

Neuron-specific enolase in cerebrospinal fluid as a biomarker of brain damage in infants with hypoxic-ischemic encephalopathy 

Alfredo Garcia-Alix*, Juan Arnaez   

  1. Neonatal Neurology, NeNe Foundation, Spain (Garcia-Alix A) 
    Neonatal Neurology, NeNe Foundation, Spain; Neonatology, Complejo Universitario de Burgos, Burgos, Spain (Arnaez J) 
  • Online:2022-02-15 Published:2021-10-08
  • Contact: Alfredo Garcia-Alix, MD, PhD, alfredoalix@gmail.com.

Abstract: Neonatal encephalopathy resulting from an asphyxial episode occurring perinatally is a major cause of death and of permanent neurological disabilities worldwide. Therapeutic hypothermia (TH) started within 6 hours of life and maintained for 72 hours is now well established as standard treatment for infants with moderate-to-severe hypoxic-ischemic encephalopathy (HIE). Those infants have altered consciousness and other signs of neurological dysfunction. However, nearly half of infants with moderate-to-severe HIE treated with TH still die or survive with disability despite treatment. In addition, the globalization of TH is still pending, especially in low-to-middle income countries where prevalence rates of HIE are particularly high.